Publications by authors named "A Gahlen"
Article Synopsis
- The study aimed to assess the long-term safety and effectiveness of tocilizumab (TCZ), an antibody that targets interleukin-6 receptors, for treating myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD).
- Researchers reviewed data from 57 patients who switched to TCZ from other treatments, monitoring relapse rates, disability status, MRI results, and more for up to 51 months.
- The results showed significant reductions in relapse rates for MOGAD and AQP4-IgG-positive patients, with many remaining relapse-free and no serious safety concerns, indicating TCZ's potential as a leading
Background And Purpose: Myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) is an inflammatory autoimmune condition of the central nervous system. However, data on pain and depression have remained scarce. The aim of this study was to assess features of chronic pain and depression as well as their impact on health-related quality of life (hr-QoL) in MOGAD.
View Article and Find Full Text PDFBackground And Purpose: Transorbital sonography (TOS) has emerged as promising imaging method for the diagnosis and follow-up of acute optic neuritis (ON). Available studies report an increase in the optic nerve diameter (OND) and the optic nerve sheath diameter (ONSD) in the case of a first episode of ON in the affected eye compared to either the contralateral unaffected eye or controls. However, the utility of TOS in the case of recurrent episodes of ON has never been assessed.
View Article and Find Full Text PDFLipid droplets (LDs) are the universal cellular storage organelles for esterified neutral lipids. The increasing number of characterized LD-associated proteins attained LDs with hitherto unexpected functions on top of their classical role as energy depot. Here, we characterize the LD-associated protein CG9186 of Drosophila by a CRISPR/Cas9-derived mutant fly line.
View Article and Find Full Text PDFApheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.
Neurol Neuroimmunol Neuroinflamm
November 2018
Objective: To analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete remission (CR).
Methods: This retrospective cohort study was based on the registry of the German Neuromyelitis Optica Study Group, a nationwide network established in 2008. It recruited patients with neuromyelitis optica diagnosed according to the 2006 Wingerchuk criteria or with aquaporin-4 (AQP4-ab)-antibody-seropositive NMOSD treated at 6 regional hospitals and 16 tertiary referral centers until March 2013.